Phase II study of pegylated liposomal doxorubicin (Caelyx) in advanced hepatocellular carcinoma (HHC).

被引：0
|
作者：
Ruff, P [1 ]
Moodley, SD [1 ]
Rapoport, BL [1 ]
Chasen, MR [1 ]
Jacobs, C [1 ]
Hacking, D [1 ]
Voroblof, DA [1 ]
机构：
[1] S African Caelyx Investigators Grp, Johannesburg, South Africa
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
306P
引用
收藏
页码：69 / 70
页数：2
相关论文
共 50 条
  • [11] Efficacy of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma
    Lind, Pehr A.
    Naucler, Gisela
    Holm, Agneta
    Gubanski, Michael
    Svensson, Christer
    ACTA ONCOLOGICA, 2007, 46 (02) : 230 - 233
  • [12] Phase I study of pegylated liposomal doxorubicin (Caelyx) in combination with Carboplatin in patients with advanced solid tumors
    Gonçalves, A
    Braud, AC
    Viret, F
    Genre, D
    Gravis, G
    Tarpin, C
    Giovannini, M
    Maraninchi, D
    Viens, P
    ANTICANCER RESEARCH, 2003, 23 (04) : 3543 - 3548
  • [13] Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx®) in combination with topotecan in patients with advanced malignancies
    Hervé Ghesquières
    Sandrine Faivre
    Latifa Djafari
    Patricia Pautier
    Catherine Lhommé
    Stéphanie Lozahic
    Kamel Djazouli
    Jean-Pierre Armand
    Eric Raymond
    Investigational New Drugs, 2006, 24 : 413 - 421
  • [14] Phase II trial of pegylated liposomal doxorubicin (Caelyx™) plus Gemcitabine in chemotherapeutically pretreated patients with advanced breast cancer
    Ulrich-Pur, Herbert
    Kornek, Gabriela V.
    Haider, Karin
    Kwasny, Werner
    Payrits, Thomas
    Dworan, Nina
    Vormittag, Laurenz
    Depisch, Dieter
    Lang, Fritz
    Scheithauer, Werner
    ACTA ONCOLOGICA, 2007, 46 (02) : 208 - 213
  • [15] Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx®) in combination with topotecan in patients with advanced malignancies
    Ghesquieres, Herve
    Faivre, Sandrine
    Djafari, Latifa
    Pautier, Patricia
    Lhomme, Catherine
    Lozahic, Stephanie
    Djazouli, Kamel
    Armand, Jean-Pierre
    Raymond, Eric
    INVESTIGATIONAL NEW DRUGS, 2006, 24 (05) : 413 - 421
  • [16] Paclitaxel and liposomal doxorubicin (Caelyx) combination in advanced breast cancer patients: a Phase II study
    Rigatos, SK
    Tsavdaridis, D
    Athanasiadis, A
    Stathopoulos, JG
    Stathopoulos, GP
    ONCOLOGY REPORTS, 2003, 10 (06) : 1817 - 1819
  • [17] A phase II study of Caelyx™ (liposomal doxorubicin) in metastatic carcinoma of the prostate:: tolerability and efficacy modification by liposomal encapsulation
    McMenemin, R
    Macdonald, G
    Moffat, L
    Bissett, D
    INVESTIGATIONAL NEW DRUGS, 2002, 20 (03) : 331 - 337
  • [18] A phase II study of Caelyx, liposomal doxorubicin: lack of activity in patients with advanced gastric cancer
    Anne L. Thomas
    Ken O'Byrne
    Lynn Furber
    Katie Jeffery
    William P. Steward
    Cancer Chemotherapy and Pharmacology, 2001, 48 : 266 - 268
  • [19] A phase II study of Caelyx, liposomal doxorubicin: lack of activity in patients with advanced gastric cancer
    Thomas, AL
    O'Byrne, K
    Furber, L
    Jeffery, K
    Steward, WP
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (04) : 266 - 268
  • [20] Evaluation of the recurrence therapy of the ovarial carcinoma by means of pegylated liposomal doxorubicin (Caelyx®)
    Steppan, I
    Sevelda, U.
    Reimer, D.
    Marth, C.
    Zeimet, A. G.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2008, 68 (04) : 435 - 435
12345